id	等位基因	注释文本
1137	*41	The CYP2D641 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D641 allele in combination with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1136	*10	The CYP2D610 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D610 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1135	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D66 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1134	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D65 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1133	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D64 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1132	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D63 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1131	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D62 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1130	*1xN	The CYP2D61xN alleles (1x2 and 1x鈮?) have been assigned as increased function alleles by CPIC. Patients carrying the CYP2D61xN allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.
1129	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.

id	证据的ID	总结
265	1184467243	CYP2D6 3 + 4 + 5 + 6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.
264	1183619031	CYP2D6 4/4 is associated with side effects when treated with amitriptyline.
263	1183617442	CYP2D6 1/4 + 2/4 + 2/5 + 4/41 + 4/10 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 1/1 + 1/2 + 2/1xN + 2/2 + 1/41 + 1/10 + 2/41.
262	1183617418	CYP2D6 4/4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 1/1.
261	1183615533	CYP2D6 4/4 is associated with toxicity when exposed to amitriptyline.
260	981476405	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.
259	1448612606	CYP2D6 normal metabolizer and ultra-metabolizer genotypes is associated with decreased likelihood of Constipation, dry mouth, Fatigue, Urinary Retention and Vision Disorders when treated with amitriptyline in people with Diabetic Neuropathies as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.
258	PA166104982	Annotation of DPWG Guideline for amitriptyline and CYP2D6
257	PA166105006	Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6

id	类型	评论
1623	Update	Added DPWG guideline as evidence
1622	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1621	Update	Updated text to include CPIC function assignments and match template. Added *2.
1620	Update	Attached CPIC guideline and removed override.
1619	Create	Created

最新招商产品更多>>